Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
MDM Policy & Practice
|
February 21, 2022
Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden
Aris Angelis
Social Science & Medicine (1982)
|
August 4, 2017
Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework
Aris Angelis, Panos Kanavos
Pharmacoeconomics
|
January 8, 2016
Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment
Aris Angelis, Panos Kanavos
Pharmaceutical Medicine
|
October 28, 2014
Acquiring Pharmaceutical Industry Assets in the UK: 1 + 1 = 1?
Panos Kanavos, Aris Angelis
British Journal of Clinical Pharmacology
|
June 13, 2020
Advancing structured decision-making in drug regulation at the FDA and EMA
Aris Angelis, Lawrence D Phillips
Applied Health Economics and Health Policy
|
October 17, 2013
Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey
David Tordrup, Aris Angelis, Panos Kanavos
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 15, 2019
An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?
Panos Kanavos, Aris Angelis, Michael Drummond
Health Policy (Amsterdam, Netherlands)
|
February 10, 2015
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
Aris Angelis, David Tordrup, Panos Kanavos
The Lancet. Oncology
|
December 5, 2024
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis
Panos Kanavos, Erica Visintin, Aris Angelis
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 18, 2017
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
Aris Angelis, Ansgar Lange, Panos Kanavos
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
MDM Policy & Practice
|
February 21, 2022
Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden
Aris Angelis
Social Science & Medicine (1982)
|
August 4, 2017
Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework
Aris Angelis, Panos Kanavos
Pharmacoeconomics
|
January 8, 2016
Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment
Aris Angelis, Panos Kanavos
Pharmaceutical Medicine
|
October 28, 2014
Acquiring Pharmaceutical Industry Assets in the UK: 1 + 1 = 1?
Panos Kanavos, Aris Angelis
British Journal of Clinical Pharmacology
|
June 13, 2020
Advancing structured decision-making in drug regulation at the FDA and EMA
Aris Angelis, Lawrence D Phillips
Applied Health Economics and Health Policy
|
October 17, 2013
Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey
David Tordrup, Aris Angelis, Panos Kanavos
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 15, 2019
An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?
Panos Kanavos, Aris Angelis, Michael Drummond
Health Policy (Amsterdam, Netherlands)
|
February 10, 2015
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
Aris Angelis, David Tordrup, Panos Kanavos
The Lancet. Oncology
|
December 5, 2024
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis
Panos Kanavos, Erica Visintin, Aris Angelis
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 18, 2017
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
Aris Angelis, Ansgar Lange, Panos Kanavos
Page
of 3